Abstract:Cancer remains a primary threat to human lives. Recently, amplification of tumor-associated reactive oxygen species (ROS) has been used as a boosting strategy to improve tumor therapy. Here, we report on a bone-targeting prodrug mesoporous silica-based nanoreactor for combined photodynamic therapy (PDT) and enhanced chemotherapy for osteosarcoma. Because of surface modification of a bone-targeting biphosphate moiety and the enhanced permeability and retention effect, the formed nanoreactor shows efficient accumulation in osteosarcoma and exhibits long-term retention in the tumor microenvironment. Upon laser irradiation, the loaded photosensitizer chlorin e6 (Ce6) produces in situ ROS, which not only works for PDT but also functions as a trigger for controlled release of doxorubicin (DOX) and doxycycline (DOXY) from the prodrugs based on a thioketal (<i>TK</i>) linkage. The released DOXY further promotes ROS production, thus perpetuating subsequent DOX/DOXY release and ROS burst. The ROS amplification induces long-term high oxidative stress, which increases the sensitivity of the osteosarcoma to chemotherapy, therefore resulting in enhanced tumor cell inhibition and apoptosis. The as-developed nanoreactor with combined PDT and enhanced chemotherapy based on ROS amplification shows significant promise as a potential platform for cancer treatment.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acsami.0c08992?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acsami.0c08992</a>.1H NMR spectra of TK, DOX-TK, and DOX-TK-DOXY; inverted fluorescence microscopy images and cell apoptosis with TUNEL staining and cell cycle analyses of OS-732 cells; loading contents of Ce6 for /MSN/DOX-TK-DOXY; particle size, UV-vis absorption spectra, and DOX and DOXY release profiles of /MSN/DOX-TK-DOXY; phototriggered intracellular DOX and DOXY release; intracellular ROS production in OS-732 cells; cell apoptosis with TUNEL staining of OS-732 cells treated with /MSN/DOX-TK-DOXY; MTP measurements for /MSN/DOX-TK-DOX; OS-732 cell metabolism after different treatments; body weights of mice bearing OS-732 tumors; ROS analysis in tumor tissues after treatment with /MSN/DOX-TK-DOXY; inner ring tumor microvessel tortuosity and density; HE staining of main organs after treatment; CD31 expression and RT-PCR analyses of tumor vessels; and quantification of DOX and DOXY contents in major organs (<a class="ext-link" href="/doi/suppl/10.1021/acsami.0c08992/suppl_file/am0c08992_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

Catalytic Effectiveness of Synchrotron and Synchrocyclotron Radiations on Osmium Dioxide (OsO2) and Osmium Tetroxide (OsO4) Nano Capsules Delivery in DNA/RNA of Cancer Cells

One-Pot Synthesized Nano-Heterostructure with Dual-Modal Catalytic ROS Generation Ability for High-Metastatic Orthotopic Osteosarcoma Therapy

The Effect of Solution Molarity on the Structural, Morphological, Optical and Electrical Properties of Nanostructured Cadmium Oxide (CdO) Nano Thin Films as Anti-Cancer Nano Drug in Cancer Cells, Tissues and Tumors under Synchrotron and Synchrocyclotron Radiations

Cadmium oxide (CdO) nanoparticles–based drug delivery in cancer prevention, prognosis, diagnosis, imaging, screening, treatment and management and its role and application in overcoming drug resistance under synchrotron and synchrocyclotron radiations

Removal Role, Application and Effect of Nanocluster Rhenium (IV) Oxide (ReO2), Rhenium Trioxide (ReO3) and Rhenium (VII) Oxide (Re2O7) Thin Films Delivery in DNA/RNA of Cancer Cells under Synchrotron and Synchrocyclotron Radiations

Advanced Studies on the Effect of Transition Metal Doped Iridium (IV) Oxide (IrO2) Nano Thin Films in Cancer Cells, Tissues and Tumors under Synchrotron and Synchrocyclotron Radiations

Rhodium (III) Oxide or Rhodium Sesquioxide (Rh2O3) and Rhodium (IV) Oxide (RhO2) Effect on the Stop Growth of Cancer Cells, Tissues and Tumors under Synchrotron and Synchrocyclotron Radiations

Progress in research on rhodium (III) oxide or rhodium sesquioxide (Rh2O3) and rhodium (IV) oxide (RhO2) nanoparticles in cancer prevention, prognosis, diagnosis, imaging, screening, treatment and management under synchrotron and synchrocyclotron rad

Annealing Effects on the Interband Transition and Optical Constants of Ruthenium (IV) Oxide (RuO2) and Ruthenium (VIII) Oxide (RuO4) Nano Thin Films in Cancer Cells, Tissues and Tumors under Synchrotron and Synchrocyclotron Radiations

Active targeting of rhenium (iv) oxide (ReO2), rhenium trioxide (ReO3) and rhenium (vii) oxide (Re2O7) nanoparticles as cancer therapeutics swell-up to kill cancer cells under synchrotron and synchrocyclotron radiations

Hollow Co-CeO2@PEG Nanospheres: Ultrasound Enhanced Cascade-Nanozyme for Synergetic Anticancer

Effect of oxygen generating nanozymes on indocyanine green and IR 820 mediated phototherapy against oral cancer

Amplification of Oxidative Stress by Lipid Surface-Coated Single-Atom Au Nanozymes for Oral Cancer Photodynamic Therapy

Iridium Oxide-Doped Calcium Phosphate Nanoparticles for Chemodynamic Therapy of Cancer

Catalytic Radiosensitization: Insights from Materials Physicochemistry

In Situ Polymerized Hollow Mesoporous Organosilica Biocatalysis Nanoreactor for Enhancing ROS‐Mediated Anticancer Therapy

Synthesis of Iridium-Based Nanocomposite with Catalase Activity for Cancer Phototherapy

Nanoarchitectonics with metal-organic frameworks and platinum nanozymes with improved oxygen evolution for enhanced sonodynamic/chemo-therapy

Synergistic cerium oxide nanozymes: targeting DNA damage and alleviating tumor hypoxia for improved NSCLC radiotherapy efficiency

Bone-Targeting Prodrug Mesoporous Silica-Based Nanoreactor with Reactive Oxygen Species Burst for Enhanced Chemotherapy

"Four-in-One" Nanozyme for Amplified Catalytic-Photothermal Therapy